Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Increasingly, IO researchers and biotech R&D teams are prioritising localised IL-12 delivery mechanisms that target tumours directly. Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy. The foreground membrane proteins (dark blue) are T-cell receptors. References: M; LWR.
98 
Let's personalize your content